Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurinia’s Dosing Patent For Lupkynis A ‘Slippery Slope’ To Extending US Market Exclusivity?

Executive Summary

The Institute for Clinical and Economic Review raises concerns about the cost implications of companies obtaining extended market exclusivity by patenting the treatment protocol used for drugs in clinical trials.

You may also be interested in...



Flurry Of Drug Pricing Bills Offer US Congress Range Of Policy Options

If pharma got to choose, it would pick the bills that seek to discourage price increases instead of the ones that allow the government to negotiate drug prices or use international reference pricing. It is unclear whether any legislation will pass, but without a Republican majority in the Senate, the risk for industry has never been greater.

New Lupus Nephritis Treatments Are Cost Effective, ICER Determines

GSK's Benlysta and Aurinia's Lupkynis for lupus nephritis are priced in line with the drug pricing watch dog's health benefit price benchmark ranges.

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel